MOMasahiro Ohara

Masahiro Ohara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masahiro Ohara has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Akihiko Osaki

    Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan

    3 shared publications
  • Asami Nukui

    Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan

    3 shared publications
  • Aya Asano

    Department of Breast Oncology, Saitama Medical University Hospital, Moroyama‑machi, Saitama 350‑0495, Japan

    3 shared publications
  • Ayako Nakame

    Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan

    3 shared publications
  • Hiroko Shimada

    Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan

    3 shared publications
  • Hiroshi Ishiguro

    Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan

    3 shared publications

Latest Publications

  • Open Access

    Occult breast cancer showing a marked response to pembrolizumab plus gemcitabine and carboplatin therapy complicated by immune‑related colitis: A case report

    by Wakako Inohana, Masahiro Ohara, Emi Mikami, Taeko Kurosawa, Ayako Nakame, Ayaka Sakakibara, Akihiro Fujimoto, Yuki Ichinose, Asami Nukui, Aya Asano, et al.

    Occult breast cancer (OBC) is a rare condition presenting with axillary or distant lymph node metastases without a detectable primary tumor. Immune checkpoint inhibitors (ICIs) show promise in triple-negative breast cancer (TNBC) treatment; however, their efficacy in OBC remains unclear. The present study describes the case of a 71-year-old woman who presented with left cervical and axillary lymphadenopathy. 18F-fluorodeoxyglucose positron emission tomography-computed tomography (CT) and breast ultrasonography revealed no detectable primary breast lesion. Core needle biopsy of the axillary lymph node confirmed the diagnosis of TNBC (estrogen receptor, 0%; progesterone receptor, 0%; human epidermal growth factor receptor 2 score, 0). The programmed death-ligand 1 combined positive score was >10. Since the patient had stage IV disease with the biological subtype defined by lymph node biopsy, breast magnetic resonance imaging was not performed to avoid delaying systemic therapy. Pembrolizumab (Pembro) combined with gemcitabine and carboplatin was initiated. However, the patient developed a Grade 1 rash after the first cycle and diarrhea after the second cycle, followed by immune-related colitis requiring hospitalization. Notably, the emergence of immune-related adverse events (irAEs) paralleled a marked treatment response, with non-contrast CT after three cycles showing complete resolution of left axillary lymph node metastases. Pembro was discontinued, and the patient has maintained a complete response on eribulin monotherapy for >1 year. The present case suggests an association between irAEs and the clinical effectiveness of ICIs, highlighting the potential of Pembro-containing chemotherapy for OBC treatment, and emphasizing the importance of prompt irAE recognition and management. Lymph node-dominant disease may represent a particularly immunogenic context for ICI therapy.


  • Open Access

    Compartment-Specific CD138 Expression Defines an Aggressive Breast Cancer Phenotype with Distinct Transcriptomic Features

    by Kyoko Asai, Takahiro Hasebe, Masahiro Ohara, Masataka Hirasaki, Kazuo Matsuura, Hiroshi Ishiguro, Akihiko Osaki, Toshiaki Saeki

    Background/Objectives: CD138 (syndecan-1) is a cell-surface heparan sulfate proteoglycan involved in cell–matrix interactions and growth factor signaling, and it has been implicated in tumor progression. However, the clinical significance of compartment-specific CD138 expression in breast cancer remains unclear. In this study, we investigated the prognostic and transcriptomic features of compartment-specific CD138 expression in invasive breast cancer. Methods: We performed an integrated analysis of immunohistochemistry and RNA sequencing of 111 invasive ductal carcinoma specimens. Tumors were classified into four groups according to CD138 expression in the tumor and stromal compartments. Clinicopathological data and survival outcomes were obtained from medical records, and transcriptomic profiles were analyzed using RNA sequencing. Results: The tumor-positive/stroma-negative phenotype (Group 1) was associated with poorer recurrence-free survival than the other phenotypes. According to multivariable Cox regression analysis, Group 1 remained an independent prognostic factor after adjustment for age, lymph node status, and Ki-67 index (hazard ratio, 5.493; p = 0.0028). Group 1 was also associated with lymph node metastasis and HER2 expression. All brain metastases occurred in Group 1, although the number of events was low. Transcriptomic profiling identified the upregulation of small nucleolar RNAs in Group 1 tumors, with the enrichment of pathways related to ribosome biogenesis, RNA processing, and translational regulation. Conclusions: Compartment-specific CD138 expression identifies an aggressive breast cancer phenotype with distinct transcriptomic features. This phenotype may have prognostic value and warrants validation using larger, independent cohorts.

  • Open Access

    Association between tumor-infiltrating lymphocytes and oncotype DX estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 single gene scores in hormone receptor-positive/HER2-negative breast cancer

    by Masahiro Ohara, Emi Mikami, Wakako Inohana, Taeko Kurosawa, Ayako Nakame, Ayaka Sakakibara, Yuki Ichinose, Akihiro Fujimoto, Asami Nukui, Aya Asano, et al.

    Introduction: Tumor-infiltrating lymphocytes (TILs) are established biomarkers in triple-negative and human epidermal growth factor receptor 2 (HER2)-positive breast cancers; however, their clinical significance in hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer remains unclear. This study aimed to investigate the association between TILs and Oncotype DX single gene scores for estrogen receptor (ER), progesterone receptor (PgR), and HER2 in HR+/HER2− breast cancer. Methods: We retrospectively analyzed 260 patients with HR+/HER2− breast cancer who underwent surgery and Oncotype DX testing at Saitama Medical University International Medical Center between January 2022 and October 2024. TILs were evaluated on hematoxylin and eosin–stained slides according to the International TILs Working Group 2014 guidelines, with high TILs defined as ≥10%. Associations between TILs, clinicopathological factors, and Oncotype DX single gene scores were examined using statistical analyses, including logistic regression. Additionally, publicly available data from The Cancer Genome Atlas (TCGA) cohort were analyzed for validation. Results: High TIL levels were observed in 32 cases (12.3%). Tumors with high TILs showed significantly lower Oncotype DX single gene expression of ER (9.8 ± 1.9 vs. 10.5 ± 1.3, p < 0.01), PgR (6.3 ± 2.2 vs. 7.4 ± 1.8, p < 0.01), and HER2 (8.5 ± 0.7 vs. 9.2 ± 0.6, p < 0.001) compared with tumors with low TILs. Multivariate analysis identified node-negative status (odds ratio [OR]: 0.266; p = 0.0159) and lower HER2 single gene expression (OR: 0.293; p = 0.00144) as independent predictors of high TILs. TCGA analysis confirmed that lower HER2 mRNA expression was associated with increased chemokine gene expression. Discussion: In HR+/HER2− breast cancer, tumors with lower HER2 mRNA expression exhibit higher lymphocytic infiltration, suggesting the presence of a distinct immunologically active subset. Oncotype DX single gene scores, particularly HER2, may provide information beyond recurrence risk prediction and help identify patients who may benefit from immune-modulating therapeutic strategies.


  • Open Access

    G-CSF-induced Aortitis in an elderly woman successfully managed with prednisolone: a case report and literature review

    by Taeko Kurosawa, Masahiro Ohara, Ayako Nakame, Yuki Ichinose, Akihiro Fujimoto, Asami Nukui, Kei Yamaguchi, Aya Asano, Hiroko Shimada, Hideki Yokogawa, et al.

    Cancer incidence among old is increasing. Since age is important risk factor for febrile neutropenia (FN), use of granulocyte-colony stimulating factor (G-CSF) and its complication is clinically important. A 72-year old woman has completed definitive surgery for left breast cancer and was started on postoperative chemotherapy. After 12 doses of paclitaxel, she received 1st cycle of epirubicin and cyclophosphamide (day 1), and pegfilgrastim, a pegylated G-CSF to decrease the risk of FN (day 2). On day 13, she was admitted due to persistent fever since day 9. Laboratory tests revealed elevated neutrophil counts and C-reactive protein. Despite empirical antibiotics, her fever persisted and severe back pain developed (day 15). Contrast-enhanced computed tomography revealed wall thickening and increased density around the aortic arch and brachiocephalic artery. Diagnosis of pegfilgrastim-induced vasculitis was made after excluding autoimmune vasculitis. Prednisolone (60 mg/day) was administered and the fever and back pain subsided the following day.